Methods for reducing immunogenicity of polypeptides
An immunogenic and biologically active technology, applied in chemical instruments and methods, biochemical equipment and methods, peptides, etc., can solve problems such as loss of HLA-DM activity
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Examples
Embodiment Construction
[0076] In particular, the invention provides modified polypeptides with reduced ability to be presented to the immune system via the MHC class II pathway. In a first embodiment, the polypeptide is modified by amino acid substitutions which alter one or more specific amino acid residues in the polypeptide chain to their respective D-isomeric forms.
[0077] Inclusion of a single D-amino acid in a polypeptide is known to disrupt binding to the MHC class II binding groove. US 5,679,640 shows that D-amino acid substitutions need to be made at critical contact sites of peptide MHC complexes, and that substitutions at non-critical sites are tolerated in MHC / peptide complexes. The aim of the present invention is to use D-amino acid substitutions to disrupt binding in the MHC class II binding pocket so that the peptide cannot be presented to the TCR. This differs significantly from the approach taught in US5,679,640, where substitutions occur at non-critical binding residues, where t...
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More